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ABSTRACT
Introduction: Although bDMARDs are effective
in the treatment of RA, they are associated with
dose-dependent side effects, patient burden,
and high costs. Recently, many studies have
investigated the possibility of discontinuing or
tapering bDMARDs when patients have reached
their treatment goal. The aim of this review is to
provide a narrative overview of the existing
evidence on bDMARD dose reduction and to
provide answers to specific dose-reduction-re-
lated questions that are of interest to clinicians.
Methods: We systematically searched for rele-
vant studies in four scientific databases. Fur-
thermore, we screened the references of reviews
and relevant studies.
Results: Our searches resulted in 45 original
studies of bDMARD dose reduction in RA
patients (15 RCTs and 30 observational studies).
Current evidence shows that bDMARD dose
reduction can be considered in all RA patients
who achieve stable (e.g., C6 months) low dis-
ease activity or remission. The best strategies
seem to be disease-activity-guided dose opti-
mization and fixed dose reduction, since direct
bDMARD discontinuation (without restarting)
results in a high flare rate, worse physical
functioning, and more joint damage. When
tapering the bDMARD treatment of a patient,
disease activity should be monitored closely,
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and if a flare occurs, the dose should be
increased to the lowest effective dose. Current
evidence shows that restarting bDMARD treat-
ment is effective and safe. Unfortunately, no
clear predictors of successful dose reduction
have been identified so far.
Conclusion: The current evidence and rising
healthcare costs urge that dose reduction
should be considered for eligible patients.
However, the decision to start dose reduction
should be made in shared decision-making.
Future research should focus not only on a
better understanding of the effects of dose
reduction on clinical outcomes but also on the
perspectives of patients and physicians as well
as the implementation of this new treatment
principle.
Keywords: bDMARDs; Discontinuation; Dose
de-escalation; Dose reduction; Dose titration;
Drug holiday; Rheumatoid arthritis; Spacing;
Tapering; Treatment relaxation
INTRODUCTION
Background
The introduction of biological disease-modify-
ing antirheumatic drugs (bDMARDs) almost
two decades ago has improved the treatment of
patients with rheumatoid arthritis (RA) by
offering more treatment options to be used
according to the tight control principle.
bDMARDs improve clinical, functional, and
radiographic outcomes, and are a welcome—
although not clearly superior—addition to
existing therapies with synthetic DMARDs
(sDMARDs) such as methotrexate, leflunomide,
and prednisone [1]. bDMARDs can be catego-
rized into those that act as an inhibitor of tumor
necrosis factor (TNFi) and those that have
another mechanism of action (non-TNFi).
Although bDMARDs are effective in the
treatment of RA, they are associated with high
costs, patient burden, and dose-dependent side
effects, such as an increased risk of infection
[2–5]. Because of these downsides, many studies
have recently investigated the possibility of
discontinuing or tapering bDMARDs when
patients have reached their treatment goal,
which is most often low disease activity (LDA)
or remission [6, 7]. Based on evidence from
these studies, the EULAR and ACR have incor-
porated the option of dose reduction into their
latest guidelines, the central axiom being
‘‘maintenance of treatment goal does not nec-
essarily mean maintenance of treatment inten-
sity’’ [8, 9].
For clinical practice, however, several ques-
tions about the optimal strategy for dose
reduction/discontinuation need to be answered
in order to properly implement bDMARD dose
optimization. Therefore, the goal of this review
is to provide a narrative overview of the existing
evidence on this topic, to provide answers to
specific dose-reduction-related questions that
are of interest to clinicians, and to suggest
topics for future research.
Questions
We aimed to answer the following clinically
relevant questions when considering dose
reduction of a bDMARD in an individual RA
patient with low disease activity:
1. What are the mechanisms behind the
possibility of bDMARD dose reduction in
RA patients?
2. In which patients and when should we
consider dose reduction?
3. What is the best dose-reduction strategy?
4. What proportion of the patients can be
stopped or tapered, and can we predict
successful dose reduction using patient or
treatment characteristics?
5. What are the effects of dose reduction on
function, quality of life, adverse events,
and radiographic damage?
6. Which flare criterion is best to use when
deciding whether to restart/re-escalate
treatment, and how often should the
patient be monitored?
7. Is it effective and safe to restart treatment?
8. What is the cost-effectiveness of dose
reduction?
9. How can dose reduction best be imple-
mented in clinical practice?
2 Rheumatol Ther (2017) 4:1–24
10. What is the patient perspective on
bDMARD dose reduction?
METHODS
To find relevant studies for this review, we
searched CENTRAL, MEDLINE, EMBASE, and
Web of Science (only for TNFi) from January 1,
1995 to August 17, 2016. We performed sepa-
rate searches for TNFi bDMARDs and non-TNFi
bDMARDs. To be included in this review, stud-
ies had to address RA, dose reduction/discon-
tinuation/tapering of bDMARDs after LDA or
remission, and at least one of the topics that we
identified for this review. Articles describing
original research, C20 participants, and a fol-
low-up of C6 months were included. Further-
more, we identified relevant reviews on the
topic of bDMARD dose reduction. The search
strategies are provided in Appendix 1 of the
Electronic supplementary material (ESM).
We also sought relevant studies by screening
the references included in reviews of this field
and those included in the studies that had
already been accepted for inclusion in this
work. In addition, studies that were already
known to the authors from previous research,
meetings/conferences, or personal communica-
tions were considered for inclusion. No
meta-analyses were performed because our aim
was to answer several questions in a narrative
manner and not to obtain summarized esti-
mates for one or two outcomes. For the same
reason, and also due to feasibility, we did not
formally assess the risk of bias in the included
studies.
Since this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects per-
formed by any of the authors, no ethical
approval was necessary.
RESULTS
General Results
Our searches and the subsequent reference
screening process resulted in 45 original studies
of bDMARD dose reduction in RA patients after
attainment of low disease activity or remission
(Table 1). Fifteen of these studies were ran-
domized controlled trials (RCTs) that were
specifically designed to compare dose reduction
with continuation of bDMARDs. The other 30
articles addressed research in which dose
reduction was investigated in a nonrandomized
manner (observational), or in which one arm of
a randomized study fulfilled the inclusion cri-
teria but a nontapering control group was not
included. The first study of this subject was
published in 2002, and there was an evident
increase in the number of studies published on
this topic in the years that followed. Most of the
studies focused on TNFi reduction (especially
etanercept and adalimumab). None of the
studies investigated anakinra or golimumab
reduction, and very few focused on cer-
tolizumab pegol reduction.
There is marked methodological hetero-
geneity among these studies (as has already
been noted by Yoshida et al. and Fautrel et al.
[6, 10]) in terms of, for example, the design
itself (RCTs, extensions of RCTs, observational
studies, and superiority versus non-inferiority
designs), inclusion criteria for dose reduction
(remission or LDA with variety in duration,
with or without concomitant DMARD, taper-
ing soon after the start of treatment or in a
later phase), and the definition of flare. How-
ever, for the latter, criteria based on the Disease
Activity Score in 28 joints (DAS28) were mostly
used.
We found several reviews on the topic of
bDMARD dose reduction. A Cochrane review
was published in 2014 by van Herwaarden et al.
that focused on down-titration and discontin-
uation of TNFi therapy [7]. However, its results
were based on searches performed in September
2013. Because many new studies and full texts
have been published since then, an update is
needed. Some reviews have chosen to focus on
dose reduction of both biological and synthetic
DMARDs; examples include the recent reviews
of Kuijper et al. and Schett et al. and a narrative
review by Fautrel et al. [6, 11, 12]. Other
reviews, such as those by Navarro-Millan et al.,
Yoshida et al., and Galvao et al. [10, 13, 14],
only focus on bDMARD discontinuation.
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The terminology used in the studies varies
considerably. Therefore, in Table 2 we propose
definitions of several terms that we will use in
this review to describe concepts of interest.
1. What Are the Mechanisms Behind
the Possibility of bDMARD Dose Reduction
in RA Patients?
Most bDMARDs are believed to work though
the achievement of a certain drug level in the
blood that remains above the minimal effective
drug concentration during the whole interval
between two administrations [61]. The dose
needed to obtain such a trough drug level differs
between patients due to variations in the vol-
ume of distribution and the half-life of the drug.
Furthermore, the minimal effective drug con-
centration varies significantly between patients.
Therefore, each patient has their own dose–re-
sponse curve [6].
Several dose–response patterns might be
possible (Fig. 1). While some patients have an
‘‘average’’ dose–response curve, other patients
will have a curve that is shifted to the left (good
clinical response on a lower dose) or shifted to
the right (good response only on a higher dose).
Also, it is conceivable that some patients have a
partial response to the drug or do not respond
to the medication at all. The latter patients are
doing well irrespective of the drug, possibly due
to the placebo effect (in RCTs), regression to the
mean, or concomitant medication.
Conceptually, based on the possible response
patterns, patients with a flat dose–response
curve can discontinue the bDMARD, as the
clinical effect is unrelated to treatment. For
patients with an S-shaped dose–response curve,
tapering is possible until the minimal effective
concentration (the concentration below which
disease activity increases) is reached. Patients
with a partial response should be switched to
another drug and patients with a dose–response
curve shifted to the right would need a higher
than standard dose. However, administering a
higher dose is not a realistic option for
bDMARDs, as the authorized dose of these drugs
is based on maximal effect at the group level.
So, the chance of response is low, and is in fact
much lower than the chance of response after
switching to another bDMARD. Also, this
higher dosing will result in lower cost-effec-
tiveness and increased risk of side effects [5, 6].
2. In Which Patients and When Should We
Consider Dose Reduction?
For clinical practice, it is important to know
which patients are eligible for dose reduction.
Logically, dose reduction is only applicable in
Table 2 Terms used in this ﬁeld
Terms Deﬁnition
Dose reduction, treatment relaxation/
de-intensiﬁcation/de-escalation
Overarching term for all strategies using dose reduction or cessation of a
bDMARD
Discontinuation, stopping Directly stopping the bDMARD
Treatment holiday Temporary discontinuation of all (or one speciﬁc) medication
Drug-free remission (DRF) Remission without any type of DMARD treatment
Fixed dose reduction Directly reducing the dose or increasing the interval of the bDMARD
Tapering Reducing the dose or increasing the interval of the bDMARD stepwise
Disease-activity-guided dose optimization,
dose titration
Tapering a bDMARD until loss of response. In the case of loss of response,
the dose is increased again until response is regained
Flare, loss of response, relapse Increase in disease activity of sufﬁcient duration and severity to warrant
treatment change. When this occurs after dose reduction, it is often called
loss of response or relapse [60]
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patients in whom the treatment goal is reached
and treatment would normally remain
unchanged. These are RA patients who have
LDA or remission on treatment with a
bDMARD.
Most of the studies included patients who
showed sustained LDA or remission for
C6 months. This period of 6 months seems
reasonable, but this is based on expert opinion
rather than evidence [6, 9]. It could be argued
that dose reduction should only be performed
in patients in clinical remission and not in
patients with a low disease activity state. How-
ever, in a recent systematic review (mentioned
in the section addressing question 4), neither
DAS28-ESR nor DAS28-CRP at baseline demon-
strated high predictive value for successful dose
reduction or discontinuation of a bDMARD.
Although deep remission is very nice to achieve,
a less stringent goal of remission or low disease
activity is a reasonable choice for many patients
because (1) the patient-acceptable symptom
state of RA disease activity is around a DAS28 of
3.2, (2) a subset of patients have a favorable
prognosis with regard to joint damage, and thus
do not need more intensive treatment, and (3)
remission is not achievable in a subset of
patients.
So, when the optimal effect of a bDMARD
has been attained, it is possible to investigate
whether this effect can be maintained with a
lower dose of the drug. However, it is important
to check that the bDMARD is not needed for
any other condition such as Crohn’s disease or
psoriasis. Also, it is also important to address the
order in which the tapering of medications
should occur. Many patients use not only a
bDMARD but also oral glucocorticoids and one
or more sDMARDs. According to the EULAR
recommendations, oral glucocorticoids should
be tapered first, bDMARDs next, and sDMARDs
last [9]. This recommendation is based on the
safety and cost-effectiveness of each drug.
In conclusion, all RA patients with sustained
(e.g., C6 months) LDA or remission, who do not
need the bDMARD for any other condition, and
who do not use high doses of steroids can be
considered for bDMARD dose reduction.
3. What is the Best Dose Reduction Strategy?
There are several possible strategies for dose
reduction of bDMARDs in RA patients. Many
studies have investigated the possibility of
direct discontinuation of the drug when a
patient is in a low disease activity state. This is
also called withdrawal, a ‘‘treatment holiday,’’
or, when remission is maintained without any
medication, drug-free remission (DFR); see also
Table 2. Another option is a fixed dose reduc-
tion, for example halving the dose. The last and
perhaps most sophisticated strategy is to taper
the dose of the bDMARD step by step until
disease flare or discontinuation of the medica-
tion. These last two strategies (fixed dose
reduction or disease-activity-guided dose opti-
mization) may be realized by either reducing
the dose or increasing the interval between
doses (spacing). Increasing the interval is the
most practical approach for drugs administered
through prefilled syringes, whereas dose reduc-
tion might be preferable for intravenous medi-
cation, as this is pharmacologically more
Fig. 1 Possible dose–response patterns for bDMARD treatment in RA patients (ﬁgure adapted from Fautrel et al. [6])
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efficient when a minimal effective trough con-
centration must be obtained for a drug with
first-order pharmacokinetics [6]. It should be
noted, however, that in RA treatment the
overarching strategy is characterized by tight
control, so this should be incorporated into any
dose-reduction strategy [62].
Based on most of the studies and reviews, it
is evident that direct discontinuation of a
bDMARD ultimately leads to a disease flare in
many or even most patients [13, 17, 26, 28, 29].
At the group level, this strategy is therefore
probably inferior to continuation of the
bDMARD with respect to disease control,
although no studies have investigated a strategy
in which direct discontinuation was combined
with restarting under tight control. However,
direct discontinuation is feasible for at least a
relevant subset of patients, which makes it
interesting to identify these patients before-
hand (see question 4).
Fixed dose reduction and disease-activ-
ity-guided dose optimization have often been
found to be noninferior to continuation of the
drug [7, 17, 22, 24–27, 63]. These strategies
should therefore be considered in daily prac-
tice, as suggested by the EULAR and ACR in
current guidelines [8, 9]. One strategy for dis-
ease-activity-guided dose optimization is to
attempt tapering only once (as in the DRESS
study [25]). Another option is to taper again
after remission has been re-achieved (as in the
STRASS study [22]). As it seems that patient
dose–response curves are relatively stable over
the short term, repeated tapering attempts are
probably not favorable. This may be why the
spacing arm in the STRASS study has a slightly
higher mean DAS28 value than the mainte-
nance arm. It may, however, be reasonable to
expect (although this should be investigated)
that another tapering attempt could be con-
sidered after a longer period, for example 1 or
2 years.
There is a discrepancy between the results of
blinded fixed dose reduction of etanercept and
open-label disease-activity-guided dose taper-
ing: having the dose was shown to be just as
effective as full-dose continuation (and thus
feasible in nearly 100% of patients), while
open-label tapering was not feasible in 30–40%
of patients. An explanation for this may be that
doubling the interval is not exactly the same as
halving the dose. Another, more likely, expla-
nation might be the nocebo and attribution
effects that are introduced when dose reduction
is not blinded. Patients might perceive dose
reduction as being inferior and may feel worse
as a result (nocebo), or unrelated events may be
falsely attributed to the dose reduction (causal
attribution) [6]. There are currently no known
interventions for countering these effects of
nocebo and false causal attribution, so
open-label dose reduction strategies will proba-
bly underperform in clinical practice compared
to what is biologically and pharmacologically
possible.
To summarize the findings, open-label dis-
ease-activity-guided dose optimization seems to
be the best strategy in clinical practice,
although this probably underperforms com-
pared to blinded dose halving as done in RCTs.
It may be best to perform one attempt at
tapering and thereafter maintain the lowest
effective dose that was found, as multiple
tapering attempts can result in higher disease
activity. Fixed dose halving is a good alterna-
tive, but disease activity should be monitored,
and of course the benefits are less compared to
tapering until stop. Direct stopping can be
attempted, but the relapse risk is much higher,
and no studies have shown noninferiority of a
stop strategy with restart in case of flaring
compared to bDMARD continuation.
4. What Proportion of the Patients Can Be
Stopped or Tapered, and Can We Predict
Successful Dose Reduction Using Patient
or Treatment Characteristics?
Although the percentage of patients who can
successfully stop or taper varies considerably
between studies, and depends on the flare cri-
teria used (see question 6), many more patients
can taper than can discontinue. For direct
bDMARD discontinuation, the relapse risk after
one year lies between 45% and 88% [6]. For
fixed bDMARD dose reduction, these numbers
are much lower—around 40% in the PRESERVE
trial, 50% in the DOSERA trial, and 34% in the
ALLOW study [17, 26, 27]. Two reviews con-
clude that halving the dose of etanercept and
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rituximab is as effective as continuing with the
full dose [7, 63].
For tapering strategies, the relapse rate
should be interpreted differently, since tapering
is continued until a patient flares (in order to
find the optimal dose). In the DRESS study, the
occurrence of short-lived flares was 73% in the
tapering arm versus 23% in the continuation
arm. However, there was no difference in per-
sistent flares (longer than 3 months): 12% ver-
sus 10% in the tapering and continuation arms,
respectively. The STRASS trial found compara-
ble relapse rates: 77% (tapering) and 47%
(continuation), although noninferiority could
not be established due to lower than projected
inclusion rates [22, 25].
The flare rate is thus lower for bDMARD fixed
dose reduction versus bDMARD discontinua-
tion. Open-label disease-activity-guided dose
optimization leads to a high risk of short-lived
flare versus continuation but comparable
long-term disease control. Finally, fixed dose
reduction seems as effective for two bDMARDs.
These quantitative chances of successful dose
reduction or discontinuation can be communi-
cated to patients, and following shared deci-
sion-making (SDM), dose reduction can be
attempted.
The chance of a successful dose reduction
may differ between patient groups, depending
on the patient or treatment characteristics.
Therefore, many studies have also investigated
possible predictors of success. Prediction of
successful dose reduction or discontinuation of
a bDMARD would provide several advantages.
In patients who cannot use a lower dose, flares
can be prevented by not tapering at all. For
patients who are able to directly stop their
bDMARD, accurate prediction would save time
and medication since the dose-tapering phase
can be skipped.
Regarding disease duration, a review by
Kavanaugh reports that withdrawal appears
possible for a subset of patients, especially those
with early disease [64]. However, their conclu-
sion is not consistent with a more recent review
by Kuijper et al. in which the flare rate in studies
including early RA patients was not consistently
lower than that in patients with established RA
[11].
Regarding the disease activity state before
dose reduction, almost all studies use the DAS28
definition of LDA or remission when deciding
upon patient inclusion [65]. Intuitively, it
might seem logical that patients in remission
have a higher chance of successful dose reduc-
tion compared to patients with low disease
activity. However, in the RETRO trial, satisfying
the ACR/EULAR Boolean remission criteria was
not associated with a lower risk of relapse
[6, 19]. Also, in the DRESS study, baseline dis-
ease activity was not a predictor of successful
tapering [6, 25]. Therefore, all patients with
LDA or in remission can be offered dose reduc-
tion with an equal chance of success.
Several dose-reduction studies have investi-
gated various biomarkers for predicting suc-
cessful tapering of bDMARDs. Some narrative
reviews have demonstrated that it remains
challenging to identify those patients who can
taper their bDMARD without risking a flare
[12, 66, 67]. In addition, the review of Schett
et al. concludes that anti-citrullinated protein
antibody (ACPA) negativity and the presence of
‘‘deep’’ remission such as absence of ultrasound
synovitis and/or normal serum markers of
inflammation are associated with greater chan-
ces of achieving drug-free remission [12].
A recent systematic review on this topic
included 16 studies with a predefined tapering
protocol and identified 64 and 52 different
biomarkers for successful discontinuation and
dose reduction, respectively. Among all the
biomarkers investigated in more than one
study, only three biomarkers were identified as
predictive in two studies: a higher adalimumab
trough level to predict successful dose reduction
and a lower Sharp/van der Heijde erosion score
and a shorter symptom duration at the start of a
bDMARD to predict successful discontinuation
[68]. The strength of this evidence was limited,
since the latter two biomarkers (erosion score
and symptom duration) showed a statistically
significant but not strong association, and the
first biomarker (adalimumab trough level) is
questionable considering the extensive multiple
testing performed in one study [69] and the
disputed results of another study [70, 71]. Also,
new data from the STRASS study could not
confirm any predictive value of adalimumab
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level [72]. In contrast to Schett et al., ACPA was
not found to be a predictor in this systematic
review, and ultrasound and several serum
markers were only studied once. Some studies
have been published recently on the Multi-
biomarker Disease Activity (MBDA) score as a
predictor of successful tapering, but they report
conflicting results [73–76].
Thus, biomarker-based prediction is not
ready for clinical practice yet. Assessment of
subclinical inflammation by laboratory or
imaging testing may provide a useful tool to
determine a patient’s risk of flare, but these
biomarkers need to be validated first in other
cohorts with a predefined tapering protocol
before they can be considered to be predictive.
The type of bDMARD used might also be an
effect modifier for successful dose reduction.
Although some bDMARDs have been more
extensively investigated than others, there do
not appear to be any large differences in the
effects of dose reduction. This may be due to the
fact that for all bDMARDs, treatment using the
authorized dose leads to overtreatment for at
least a proportion of patients, since this dose is
almost always chosen to be the highest effective
dose at the group level. Some differences do
seem to exist. For example, in the DREAM study
with tocilizumab, relapse occurred quite rapidly
[47].
Rituximab (RTX) is a rather different type of
bDMARD. It is administered at intervals of at
least 6 months due to the long B-cell depletion
effect. The authorized RTX dosing for RA is also
clearly much higher than needed. A recent
systematic review revealed that half the autho-
rized dose (1 9 1000 mg) is as effective as the
full dose (2 9 1000 mg). This low dose is now
widely used in clinical practice [77]. Several case
studies and one case series suggest the possibil-
ity that a much lower dose of rituximab might
be effective in the treatment of RA patients
[78–81]. The effectiveness of these ultralow
doses should be investigated further. Note that
retreatment with RTX can be given on demand,
but this results in repeated flaring and subopti-
mal disease control compared to fixed retreat-
ment schedules or tight control treatment [82],
as this approach essentially mimics repeated
dose reduction attempts. So, while lower dosing
can and should be used, in our opinion,
retreatment should preferably be carried out
either with a fixed interval or under strict tight
control.
Regarding sDMARD use, Kavanaugh et al.
suggest that patients who are MTX-naı¨ve and
receive an induction regimen of MTX with a
TNF inhibitor may be better suited to dose
reduction than those who do not respond to
MTX sufficiently, improve upon the addition of
a TNF blocker, and then are withdrawn from the
bDMARD [64]. This seems logical, as response in
these patients probably depends on MTX rather
than the bDMARD. In the review by Kuijper
et al., no relationship was observed between the
use of a concomitant sDMARD and time to flare
[11]. However, no information was reported on
the order in which bDMARD and sDMARDs
treatment was given before tapering. Therefore,
no clear conclusion can be drawn on the effect
of a concomitant DMARD treatment based on
these reviews.
5. What Are the Effects of Dose Reduction
on Function, Quality Of Life, Adverse Events,
and Radiographic Damage?
Since fixed dose reduction and tapering of
bDMARDs seem feasible in a large proportion of
RA patients, and discontinuation for a smaller
group, it is important to address the effects that
are found on other important clinical outcomes
such as function, quality of life, adverse events,
and progression of joint damage.
Function (measured with the HAQ-DI) was
found to be worse after discontinuation in the
PRESERVE study, but not in two other RCTs, the
OPTIMA and ADMIRE [17, 18, 28]. The
ENCOURAGE study showed that fewer patients
had HAQ\0.5 after discontinuation [21]. In the
ALLOW study, physical function was slightly
worse after withdrawal of abatacept, but this
improved after reinstating treatment [15].
Function was found to be comparable to con-
tinuation after fixed dose reduction and taper-
ing [17, 22, 25]. In the STRASS study, a small
difference in quality of life remained at the end
of the study [22].
The reduction of (dose-dependent) adverse
events is one of the reasons to consider dose
reduction of bDMARDs. Although several
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studies have monitored adverse events, few
have found significant differences between dose
reduction and continuation
[17, 18, 22, 25, 26, 28, 49]. This might be due to
the fact that none of these studies were powered
to detect differences in side effects, and clinical
trials in general have a limited follow-up time.
Also, tapering studies usually include patients
who have been using the bDMARD for quite
some time, thus selecting the patients who are
less prone to adverse effects (healthy survivor
bias). However, Raffeiner et al. did find fewer
infections in the half-dose etanercept group
compared to the full-dose group [24].
Several studies have assessed the effect of
bDMARD dose reduction on radiographic
structural damage progression. In the PRESERVE
trial, discontinuation of etanercept led to
increased joint damage. However, progression
in the dose-halving group was similar to that in
the continuation group [17]. These findings are
in line with other studies which found that dose
reduction/tapering did not lead to significant
radiographic damage progression
[22, 24, 34, 35, 54, 55]. In the DRESS study, a
minimal increase in radiographic progression
was found in the tapering group, but no
patients had an outcome of relevant joint
damage progression [25]. Kuijper et al. conclude
in their systematic review that there are limited
data on radiographic damage but that the cur-
rent evidence shows that progression remains
limited after treatment de-escalation [11].
In conclusion, discontinuation results in
somewhat worse function and more joint
damage. Fixed dose reduction and tapering does
not seem to result in deterioration in these
parameters. A reduction in adverse events has
not been unequivocally shown, although this
seems plausible, as bDMARD-induced infections
have been shown to be dose-related [4].
6. Which Flare Criterion is Best to Use When
Deciding Whether to Restart/Re-escalate
Treatment, and How Often Should the Patient
Be Monitored?
In the included studies, several different criteria
for flares were used, although they were mostly
based on the DAS28. The OMERACT working
group performed a validation study of the
DAS28-based RA flare criteria. They concluded
that an increase in DAS28[1.2, or[0.6 if DAS28
C3.2, appears to be the most discriminating and
valid based on a set of predefined validation
criteria [83]. It is therefore advisable to use this
flare criterion in clinical practice. In addition,
the OMERACT RA Flare group is developing a
patient-reported flare questionnaire that could
also be used in the future [84], especially in
health care systems where travel distances are
much higher than generally encountered in
Western Europe. Other flare criteria could be
used as well, but they may be either too sensi-
tive or too specific, resulting in worse patient
outcomes or conversely unjustified treatment
re-escalation.
Since dose reduction may lead to a flare in (a
proportion of) the patients, it is very important
to closely monitor patients who are tapering
their bDMARDs. When a flare occurs, the dose
should be increased again to the lowest effective
dose. Based on the methods of several trials, an
interval of no more than 3 months appears
necessary, with an extra consultation when
patients experience a worsening of their symp-
toms [22, 24, 25].
7. Is It Effective and Safe To Restart
Treatment?
When considering discontinuation or tapering
until stop, it is essential to know whether
restarting the bDMARD or intensifying treat-
ment will be effective and safe. Regarding effec-
tiveness, most patients are able to regain LDA or
remission again after restarting the bDMARD
treatment. Percentages of between 80% and
100% are described [85]. Also, most studies show
that restarting a bDMARD after withdrawal is
well tolerated and not associated with more
adverse events or higher immunogenicity
[15, 25, 35, 38, 44, 49, 55]. Data from tight con-
trol studies also support this notion, as the mean
DAS28 for example in the DRESS study is similar
for continuation and dose reduction after
18 months, while switching to other bDMARDs
was rare [25]. Therefore, based on the current
evidence, it seems that restarting bDMARDs after
discontinuation is effective and safe.
It has been suggested in the literature that
tapering of bDMARDs may lead to the
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formation of anti-drug antibodies (ADAbs),
which could then result in worse outcomes after
restarting treatment. However, there does not
seem any evidence supporting this statement
[85, 86]. It is probable that the amount of ‘‘free’’
antibodies that is measured depends on the
dose of the antigen (the drug). When adminis-
tering a high dose, most of the ADAbs will be
bound to the drug. When administering a low
dose, more of the ADAbs will be unbound and
are thus measureable in the blood. This does not
automatically imply that the formation of these
antibodies is increased, or that the presence of
the ADAbs leads to a lower effect or side effects.
8. What is the Cost-Effectiveness of Dose
Reduction?
Next to infection risk and patient burden due to
regular self-injection, costs are one of the main
reasons to look into dose reduction of
bDMARDs after LDA or remission is reached.
Surprisingly, not many of the studies that
address this topic report a cost analysis of their
strategy. This may be because the majority of
the studies are funded by pharmaceutical com-
panies, so there is perhaps a limited interest in
demonstrating that dose reduction is cost-ef-
fective. While it seems logical that tapering a
bDMARD will result in a substantial cost saving,
the question is whether these savings outweigh
the costs induced by increased monitoring,
patient education, an increase in flares, and a
subsequent deterioration in quality of life (as
reflected in QALYs).
Only three of the RCTs included in this
review describe a cost-effectiveness analysis: the
STRASS and DRESS studies, which both investi-
gated disease-activity-guided tapering of
bDMARDs until discontinuation, and the PRE-
SERVE study [22, 25, 87–89]. The STRASS study
found that spacing resulted in a smaller gain in
QALYs during the study period of 18 months
compared to continuation. They calculated that
53,417 euros were saved per QALY lost. The
authors indicate that it depends on the will-
ingness to accept whether this is cost-effective
[22]. In the DRESS study, the mean QALY loss
was -0.02 in the tapering arm compared to the
continuation arm, and the dose optimization
strategy resulted in savings of approximately
8000 euros per patient per year. The savings per
QALY lost were 390,493 euros. When the min-
imal QALY loss was adjusted to account for the
upper limit of what society is willing to pay or
accept in the Netherlands, the net savings were
still high [25]. For the PRESERVE study, a Mar-
kov model was devised that incorporated data
from the trial and extrapolated to 10 years fol-
low-up, allowing a dose increase in the case of a
flare and dose reduction in the case of remission
according to tight control. Overall, the fixed
dose halving strategy seemed most advanta-
geous, mainly because half-dose etanercept
showed a similar effectiveness to full-dose [89].
Three of the nonrandomized studies that we
found reported costs [37, 44, 52]. In an uncon-
trolled study of infliximab tapering by van der
Maas et al., a mean reduction of 3474 euros per
patient was found [37]. In a strategy study by
Inui et al., patients discontinued etanercept
when disease activity was low and restarted
when a flare occurred. In the 5 patients who
maintained low disease activity without
restarting etanercept, the savings were found to
be approximately 35% [44]. Murphy et al.
reported a cost saving of 600,000 euros after
2 years in their cohort of 79 patients (45 RA, 10
psoriatic arthritis, and 24 ankylosing spondyli-
tis) that reduced the dose of etanercept or
adalimumab [52]. That meant a saving of 3800
euros per patient per year—comparable to the
savings found by van der Maas et al.
Overall, disease-activity-guided dose opti-
mization results in large cost savings per patient
per year and no or a small loss in QALYs.
Cost-effectiveness estimates are, however, very
sensitive to either no or very small changes in
quality of life, so the precise cost-effectivenesses
of different strategies remain to be established,
although results seem very encouraging.
9. How Can Dose Optimization Best Be
Implemented in Clinical Practice?
An often forgotten aspect of new treatment
strategies is their implementation in clinical
practice. Although several studies have shown
the additional value of bDMARD dose reduc-
tion, and it has been incorporated into inter-
national recommendations [8, 9], this does not
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automatically mean that clinicians will act on it
[90, 91].
Several studies have investigated the current
use of a lower-than-standard dose of bDMARDs
in routine clinical practice. A systematic review
into dose escalation and dose reduction of
bDMARDs in clinical practice found that, for
etanercept, 13.2% of patients used a
lower-than-registered dose. For adalimumab
and infliximab, this was 8.9% and 25%,
respectively [92]. In a retrospective cohort of RA
patients using Medicare claims (n = 26,510),
approximately 10–20% of patients who initi-
ated and adhered to etanercept and adali-
mumab for C12 months subsequently received
reduced-dose therapy for an 12 additional
months and beyond [93]. In the Ninja cohort
(n = 1037), 7.4% of patients stopped bDMARD
treatment due to remission [94] and 40% of
patients in a tertiary hospital in Spain (n = 96)
used a lower-than-registered dose while
remaining at a low disease activity or in remis-
sion [95]. These data show that in routine clin-
ical practice, outside of trials, bDMARD dose
reduction is still relatively rare, and it is often
implemented for reasons other than dose opti-
mization (e.g., side effects), and the mean per-
centage of patients on a lower-than-registered
dose probably lies somewhere between 10% and
25%.
Many factors can impede the use of new
insights in clinical practice, such as barriers
related to the innovation itself (e.g., complex-
ity, relative advantage), the individual health
care provider or patient (e.g., knowledge, atti-
tude, skills, self-efficacy), incentives and
resources (time, funding), or the organizational
context (work climate, structures) [90, 96]. For
dose reduction, it is conceivable that rheuma-
tologists are not aware of the possibility of dose
reduction (knowledge), do not agree with the
evidence (attitude), or simply do not have the
time or tools/protocols to adhere to the guide-
lines (practical barriers). The same holds true for
patients. Since it is still difficult to predict suc-
cessful dose reduction, tapering comes with a
risk of (short-term) disease flare which makes
the decision to taper very dependent on patient
preference. Gaining insight into barriers and
facilitators for patients and physicians could
facilitate implementation.
Recently, a pilot study aiming at the imple-
mentation of tight control and bDMARD dose
optimization was published [97]. A multicom-
ponent strategy consisting of education, proto-
col development, and treatment advice was
employed to improve the use of these principles
in a tertiary hospital with two rheumatologists.
The results showed an increase in DAS mea-
surements and a large decrease in bDMARD use,
while mean disease activity levels remained
unchanged. Larger, preferably controlled, stud-
ies are necessary to assess the effectivenesses of
implementation strategies.
10. What is the Patient Perspective
on bDMARD Dose Reduction?
Since dose reduction of a bDMARD comes with
an increased risk of short-lived disease flare, the
decision to start tapering is also dependent on
the preference of each individual patient. The
physician can inform, educate, and motivate
the patient based on the current evidence on
dose reduction, but the final decision should be
SDM-based. It is therefore important to inves-
tigate what patients’ cognitions and emotions
are regarding bDMARD dose reduction.
Three qualitative studies into the patient
perspective on bDMARD dose reduction were
identified [98–100]. These studies all found that
dose reduction is associated with both positive
and negative perceived aspects for patients.
Positive aspects include the reduced risk of
adverse events, reduced frequency of injections,
and contributing to savings in the healthcare
budget. Examples of negative aspects are the
risk of a flare, a delay in access to previous doses,
and fear of a loss of efficacy after restarting
treatment.
While these qualitative studies all explore
factors that are important to patients when
considering dose reduction of a bDMARD, the
preferences of individual patients will differ
largely. However, the current evidence on dose
reduction and the need to reduce medication
costs urge that tapering in RA patients who
reach a stable LDA or remission on bDMARD
treatment should be discussed in shared deci-
sion-making. In clinical practice, a balance
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must be found between patient concerns and
the responsibility of hospitals and rheumatolo-
gists to contribute to savings in the healthcare
budget.
Communication methods could help physi-
cians in their daily work regarding bDMARD
dose reduction. Patient expectations could be
modified by informing them as early as possible
about the option of dose reduction, for example
at the start of their bDMARD treatment. Also,
motivational interviewing or positive framing
can be used in conversations about dose
reduction with individual patients.
DISCUSSION
Based on the current evidence for this subject,
we conclude that bDMARD dose reduction can
be considered in all RA patients who have stably
reached their treatment goals (e.g., C6 months
LDA or remission) on treatment with a
bDMARD. The best strategy seems to be dis-
ease-activity-guided dose tapering with fixed
dose reduction as an alternative, since the risk
of relapse was found to be highest for direct
bDMARD discontinuation, and discontinuation
results in worse physical functioning and more
joint damage. Although bDMARD tapering
seems to be (very) cost-effective, a reduction in
adverse events after dose reduction is yet to be
clearly demonstrated.
When tapering the bDMARD treatment of a
patient, disease activity should be monitored
closely, for example with a consultation every
3 months and extra consultations when neces-
sary. The validated flare criterion (DDAS28[1.2
or[0.6 if DAS28 C3.2) can be used to identify
patients who have lost response due to the
tapering. When a patient flares, the dose should
be increased to the lowest effective dose. Cur-
rent evidence shows that restarting bDMARD
treatment is effective and safe. Unfortunately,
no clear predictors of successful tapering have
been identified so far. The evidence for
bDMARD dose reduction and rising healthcare
costs urge that dose reduction should be con-
sidered and attempted for eligible patients.
However, patient values and preferences should
be respected and a balance may be found using
SDM.
This study has some limitations, as our
searches for relevant articles were systematic but
the data extraction and writing were performed
in a narrative manner. Also, we did not perform
a quality assessment of the included articles,
and no formal meta-analyses were done. How-
ever, this review does provide a complete over-
view of the most important studies that have
been performed on bDMARD dose reduction,
and the questions that we address here could be
of interest to a large group of clinicians involved
in the treatment of RA patients.
Several new trends are visible regarding
bDMARD dose reduction, such as the intro-
duction of biosimilars, which will change the
cost-effectiveness ratio for tapering [101]. Also,
evidence on bDMARD dose reduction for other
diagnoses in rheumatology is emerging, for
example in relation to psoriatic arthritis and
ankylosing spondylitis [102]. Furthermore, new
methods of research are gaining interest, such
as noninferiority trials (investigating whether a
new strategy or treatment is no worse than the
old one) and modeling studies (using existing
data to answer new research questions, thus
saving costs and limiting the burden on
patients) [103, 104]. Lastly, it is clear that most
of the research done on the topic of dose
reduction is ‘‘hard science,’’ and studies of the
‘‘soft science’’ associated with dose reduction
(e.g., investigations of SDM and implementa-
tion) are lagging behind. Future research should
focus not only on achieving a better under-
standing of the effects of dose reduction on
important clinical outcomes but also on the
perspectives of the patients and physicians as
well as the implementation of this new treat-
ment principle.
CONCLUSIONS
In conclusion, a lot of research has been done
on the topic of bDMARD dose reduction in RA.
The best dose-reduction strategies seem to be
disease-activity-guided dose optimization and
fixed dose reduction. The evidence for bDMARD
dose reduction and rising healthcare costs urge
18 Rheumatol Ther (2017) 4:1–24
that dose reduction should be considered for
and attempted in RA patients who have reached
a stable state of LDA or remission. However,
patient values and preferences should be
respected, and a balance may be found using
SDM.
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